Skip to main content
. Author manuscript; available in PMC: 2014 Oct 15.
Published in final edited form as: Cancer Res. 2013 Aug 13;73(20):6299–6309. doi: 10.1158/0008-5472.CAN-12-4082

Figure 4. Wnt and TGF-β cooperate to down-regulate GRHL2.

Figure 4

HMLE cells treated with the canonical Wnt pathway agonist BIO (a) or stably expressing β-catenin S33Y (b) were assayed for GRHL2 down-regulation in response to TGF-β treatment by Western blotting; each is one representative of two duplicate experiments. (c) HMLE cells that stably expressed Twist-ER protein were treated with or without 4-OHT (to activate Twist-ER) in the presence or absence of the TGF-β pathway antagonist BMP2, and cell lysates were assayed for GRHL2 and other indicated protein expression.